肝脏继发性神经内分泌肿瘤的影像学检查：I123间碘苄胍（MIBG）与In111标记的奥曲肽（Octreoscan）的比较

Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan).

作者信息

Ramage J K, Williams R, Buxton-Thomas M

机构信息

Institute of Liver Studies, King's College Hospital, London, UK.

出版信息

QJM. 1996 Jul;89(7):539-42. doi: 10.1093/qjmed/89.7.539.

DOI:10.1093/qjmed/89.7.539

PMID:8759495

Abstract

Functional imaging of neuroendocrine tumours with Octreoscan and I123-metaiodobenzylguanidine (MIBG) is important for assessment prior to various therapies and assessing response. The two imaging methods have not been directly compared in hepatic neuroendocrine tumours. Patients (n = 18) were studied with both imaging techniques. The sensitivity of Octreoscan was 94%, and that of MIBG 39%. No previously occult primary sites were detected. Concurrent octreotide therapy did not reduce the sensitivity of Octreoscan. Widespread bone metastases were seen in two post-liver-transplant patients using Octreoscan. Octreoscan is a sensitive means of detecting hepatic neuroendocrine tumours, and the more specific technique. MIBG has poor sensitivity, reducing its clinical utility. Therapy with I131-MIBG is likely to be applicable to relatively few patients.

摘要

使用奥曲肽扫描（Octreoscan）和碘-123间碘苄胍（I123-MIBG）对神经内分泌肿瘤进行功能成像，对于各种治疗前的评估和评估反应非常重要。这两种成像方法尚未在肝神经内分泌肿瘤中进行直接比较。对18例患者同时采用这两种成像技术进行研究。奥曲肽扫描的敏感性为94%，而MIBG的敏感性为39%。未检测到先前隐匿的原发部位。同时进行的奥曲肽治疗并未降低奥曲肽扫描的敏感性。使用奥曲肽扫描在两名肝移植后患者中发现了广泛的骨转移。奥曲肽扫描是检测肝神经内分泌肿瘤的一种敏感方法，也是更具特异性的技术。MIBG敏感性较差，降低了其临床应用价值。I131-MIBG治疗可能仅适用于相对较少的患者。